Authors: Fair, WR Rabbani, F Bastar, A Betancourt, J

Citation: Wr. Fair et al., Neoadjuvant hormone therapy before radical prostatectomy: Update on the memorial Sloan-Kettering Cancer Center trials, MOL UROL, 3(3), 1999, pp. 253-260

Authors: Balaji, KC Rabbani, F Tsai, H Bastar, A Fair, WR

Citation: Kc. Balaji et al., Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance, J UROL, 162(3), 1999, pp. 753-757

Authors: Rabbani, F Perrotti, M Bastar, A Fair, WR

Citation: F. Rabbani et al., Prostate specific antigen doubling time after radical prostatectomy: Effect of neoadjuvant androgen deprivation therapy, J UROL, 161(3), 1999, pp. 847-852

Authors: Fair, WR Bastar, A Rabbani, F

Citation: Wr. Fair et al., Pathologic stage and biochemical recurrence after radical prostatectomy and neoadjuvant hormone therapy: Effect of treatment until PSA is undetectable, MOL UROL, 2(3), 1998, pp. 135-139

Authors: Rabbani, F Dalbagni, G Bastar, A Fair, WR

Citation: F. Rabbani et al., Nomograms to predict pathologic results of radical prostatectomy: Effect of neoadjuvant hormone therapy, MOL UROL, 2(3), 1998, pp. 143-150

Authors: Rabbani, F Bastar, A Fair, WR

Citation: F. Rabbani et al., Neoadjuvant hormone therapy before radical prostatectomy: Update on Phase II and III Memorial Sloan-Kettering Cancer Center trials, MOL UROL, 2(3), 1998, pp. 151-156